Literature DB >> 26969848

Treatment of in vitro enterohemorrhagic Escherichia coli infection using phage and probiotics.

C Dini1, P A Bolla2,3, P J de Urraza1,2.   

Abstract

AIMS: To assay the combination of phage and probiotics against EHEC in vitro on infected Hep-2 cells. METHODS AND
RESULTS: Phage and probiotics treatments on EHEC O157:H7-infected Hep-2 cells were assayed individually or combined. The effect of freeze-drying on phage and probiotic antimicrobial activity was also studied. While treatment with phage alone increased cell detachment caused by EHEC infection, the treatments with MM alone or in combination with phage proved to effectively diminish cell damage caused by EHEC infection. Combined treatment showed a decrease in apoptotic cell count of 57·3% and a reduction in EHEC adhesion to cell monolayer of 1·2 log CFU. The simultaneous use of phage and probiotics showed no antagonistic effect, and freeze-drying did not affect their antipathogenic activity.
CONCLUSIONS: The combination of phage and probiotics has great potential for reducing the number of pathogens adhered to epithelial cells during EHEC O157:H7 infection and attenuating the cytotoxic effect derived from it. Further in vivo assays are needed for assessing the actual effectiveness of the treatment. SIGNIFICANCE AND IMPACT OF THE STUDY: This study presents a freeze-dried formulation of phage and probiotics capable of controlling EHEC infections and reducing epithelial cell damage in vitro.
© 2016 The Society for Applied Microbiology.

Entities:  

Keywords:  combined therapy; enterohemorrhagic Escherichia coli; kefir; phage; probiotics

Mesh:

Year:  2016        PMID: 26969848     DOI: 10.1111/jam.13124

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  6 in total

1.  Synergistic Effects of Bacteriophage vB_Eco4-M7 and Selected Antibiotics on the Biofilm Formed by Shiga Toxin-Producing Escherichia coli.

Authors:  Agnieszka Necel; Sylwia Bloch; Gracja Topka-Bielecka; Agata Janiszewska; Aleksandra Łukasiak; Bożena Nejman-Faleńczyk; Grzegorz Węgrzyn
Journal:  Antibiotics (Basel)       Date:  2022-05-25

2.  Oral Immunization with Recombinant Lactobacillus acidophilus Expressing espA-Tir-M Confers Protection against Enterohemorrhagic Escherichia coli O157:H7 Challenge in Mice.

Authors:  Ruqin Lin; Yiduo Zhang; Beiguo Long; Yawen Li; Yuhua Wu; Siqin Duan; Bo Zhu; Xianbo Wu; Hongying Fan
Journal:  Front Microbiol       Date:  2017-03-15       Impact factor: 5.640

Review 3.  Management of STEC Gastroenteritis: Is There a Role for Probiotics?

Authors:  Mario Giordano; Maria Elisabetta Baldassarre; Viviana Palmieri; Diletta D Torres; Vincenza Carbone; Luisa Santangelo; Federico Gentile; Raffaella Panza; Federica Di Mauro; Manuela Capozza; Antonio Di Mauro; Nicola Laforgia
Journal:  Int J Environ Res Public Health       Date:  2019-05-12       Impact factor: 3.390

Review 4.  Treatment Strategies for Infections With Shiga Toxin-Producing Escherichia coli.

Authors:  Sabrina Mühlen; Petra Dersch
Journal:  Front Cell Infect Microbiol       Date:  2020-05-06       Impact factor: 5.293

5.  Strain specific motility patterns and surface adhesion of virulent and probiotic Escherichia coli.

Authors:  M M Abdulkadieva; E V Sysolyatina; E V Vasilieva; A I Gusarov; P A Domnin; D A Slonova; Y M Stanishevskiy; M M Vasiliev; O F Petrov; S A Ermolaeva
Journal:  Sci Rep       Date:  2022-01-12       Impact factor: 4.379

Review 6.  AB5 Enterotoxin-Mediated Pathogenesis: Perspectives Gleaned from Shiga Toxins.

Authors:  Erika N Biernbaum; Indira T Kudva
Journal:  Toxins (Basel)       Date:  2022-01-16       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.